×
  • Category
  • Type
  • Advanced

Feasibility assessment of measles and rubella eradication

Polio Eradication Strategy 2022-2026: Delivering on a Promise

Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap

Q&A for Session #14: Monitoring and Evaluating COVID-19 Vaccine Introduction

Q&A for Session #13: Private Sector Engagement

COVID-19 Vaccine Explainer - COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm)

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study

Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions

Alteration in vaccination rates and an evaluation of physicians' perceptions of the possible impact of the SARS-CoV-2 pandemic on childhood vaccinations in Ankara, Turkey

COVID-19 disrupts vaccine delivery

Findings from a healthcare worker evaluation of the COVID19 vaccine label

Vai trò của Hệ thống Quản lý thông tin tiêm chủng quốc gia trong việc giảm tải khối lượng công việc của cán bộ y tế và nâng cao hiệu quả Chương trình tiêm chủng tại Việt Nam

Electronic Immunization Registry in Workload Reduction and Efficiency Enhancement for Immunization Program in Vietnam

COVID-19 Vaccine Introduction and deployment Costing tool (‎‎‎‎CVIC tool)

COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence

The role of health workers in COVID-19 vaccination - implementation support guide

Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

COVID-19 Vaccine Communication Resources